Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Share-based Compensation: 2016-2025

Historic Share-based Compensation for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $9.8 million.

  • Rocket Pharmaceuticals' Share-based Compensation fell 13.24% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.0 million, marking a year-over-year decrease of 1.70%. This contributed to the annual value of $43.9 million for FY2024, which is 11.46% up from last year.
  • Rocket Pharmaceuticals' Share-based Compensation amounted to $9.8 million in Q3 2025, which was down 10.11% from $10.9 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Share-based Compensation peaked at $11.3 million during Q2 2024, and registered a low of $6.3 million during Q1 2022.
  • Over the past 3 years, Rocket Pharmaceuticals' median Share-based Compensation value was $10.3 million (recorded in 2023), while the average stood at $10.4 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Share-based Compensation spiked by 99.44% in 2021, and later decreased by 20.63% in 2022.
  • Rocket Pharmaceuticals' Share-based Compensation (Quarterly) stood at $7.0 million in 2021, then skyrocketed by 37.74% to $9.7 million in 2022, then grew by 2.45% to $9.9 million in 2023, then grew by 11.66% to $11.1 million in 2024, then fell by 13.24% to $9.8 million in 2025.
  • Its last three reported values are $9.8 million in Q3 2025, $10.9 million for Q2 2025, and $10.3 million during Q1 2025.